Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools

Drug Discov Today. 2005 Feb 15;10(4):242-7. doi: 10.1016/S1359-6446(04)03265-9.

Abstract

The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Diphosphonates / therapeutic use
  • Drug Design
  • Glycoproteins / therapeutic use
  • Humans
  • Integrin alphaVbeta3 / antagonists & inhibitors
  • Molecular Mimicry
  • Osteolysis / drug therapy*
  • Osteoprotegerin
  • Peptides / chemistry
  • Receptors, Cytoplasmic and Nuclear / therapeutic use
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Signal Transduction / drug effects

Substances

  • Diphosphonates
  • Glycoproteins
  • Integrin alphaVbeta3
  • Osteoprotegerin
  • Peptides
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Tumor Necrosis Factor
  • Recombinant Proteins
  • TNFRSF11B protein, human